First TAVR for Aortic Regurgitation Moves to Phase 3 Trial

Here is some good news for Hodgkin’s survivors who suffer from cardiac failure due to aortic valve regurgitation – a common late effect for those who had chest radiation. The forward progression of this trial could ultimately mean that there are additional, far less invasive (and grueling!) options for open-heart surgery (SAVR). Hodgkin’s survivors often have complicating co-morbidities when it comes to surgical valve replacement procedures, making the use of TAVR a welcome choice.